高效液相色谱-线性离子阱串联质谱技术用于白酒中甜蜜素测定的确证分析

建立了白酒中甜蜜素的高效液相色谱-线性离子阱串联质谱测定方法。该方法可同时准确定性和定量。样品无需前处理,过膜后直接进样,由C18色谱柱分离,采用多反应监测(MRM)和触发增强子离子扫描模式检测,采集到的MRM数据用于定量测定,同时得到的高质量子离子谱图用于谱图库检索的方法进行定性确证分析。本文采用外标法定量,方法的线性范围为1.320～132.0 μg/L（r=0.9991）;检出限(信噪比为3)为0.1 μg/L;添加水平分别为2.640、26.40、100.0 μg/L的3个样品的加标回收率为96.38%～107.2%,相对标准偏差均小于9%;阳性样品的谱图匹配度均高于92%。该方法简便、准确、高效,适用于白酒中甜蜜素的测定及阳性样品的确证分析。     

纳升电喷雾串联质谱法确证阿托西班的一级结构

利用电喷雾串联质谱对合成八肽阿托西班进行了二硫键还原前后的精确分子量测定和一级结构的确证.首先通过全扫描模式测定了其还原前后的精确分子量,然后选择母离子m/z 498.73(双电荷)通过串联质谱(MS/MS)得到碎片离子,采用Y离子的方法测定了阿托西班的序列并对其的修饰位点进行了确证.本方法具有灵敏度高、速度快、样品无需纯化等特点,在多肽类药物一级结构分析方面具有独特的优势.     

纳升电喷雾串联质谱在阿托西班一级结构确证中的应用

利用电喷雾串联质谱对合成八肽阿托西班进行了二硫键还原前后的精确相对分子质量测定和一级结构的确证.首先通过全扫描模式测定了其还原前后的精确相对分子质量,然后通过串联质谱(MS/MS)得到母离子m/z 498.73(双电荷)的碎片离子,采用y离子的方法测定了阿托西班的序列并对其修饰位点进行了确证.该方法具有灵敏度高、速度快、样品无需纯化等特点,在多肽类药物一级结构分析方面具有独特的优势.     

QuEChERS-液相色谱-质谱法快速筛查和确证大米中205种农药残留

结合QuEChERS法与液相色谱-三重四极杆复合线性离子阱质谱(LC-Q-TRAP/MS)技术,建立了大米中205种农药残留的快速筛查确证方法。大米样品经乙腈提取,N-丙基乙二胺(PSA)、无水MgSO₄和C₁₈吸附剂净化后,采用多反应监测-信息关联采集-增强子离子(MRM-IDA-EPI)扫描方式及谱库检索技术,通过对化合物的保留时间、离子对以及高灵敏度的EPI谱库检索比对,完成了205种农药的筛查与确证,并采用外标法定量,实现了大米样品中205种农药的定性和定量分析。结果表明,所有农药的线性相关系数均大于0.995;方法的定量限在0.5~10.0 μg/kg之间。在10、50 μg/kg两个添加水平下,205种农药的平均回收率在62.4%~127.1%之间;相对标准偏差(RSD)在1.0%~20.0%之间。该方法能够对大米样品进行实际检测,且检测时间不超过20 min。该方法快速、准确、灵敏度高,适合于大米中农药残留的快速、全面筛查和确证分析。     

同位素内标-多反应监测同步在线质谱全扫描确证火锅料中罂粟壳成分

建立了高效液相色谱-三重四极杆线性离子阱质谱测定火锅料中吗啡、可待因、蒂巴因、罂粟碱、那可丁等5种生物碱残留的确证方法。样品采用稀盐酸加热提取,正己烷除脂,阳离子混合机理固相萃取柱净化,5%氨化乙酸乙酯-甲醇洗脱,PAK ST色谱柱分离,5 mmol/L乙酸铵甲醇溶液-10 mmol/L乙酸铵水溶液(pH 3.6)作为流动相洗脱,电喷雾正离子模式下多反应监测同步增强子离子在线全扫描(EPI)。在该实验条件下,5种生物碱的LOD在0.05~0.5 μg/kg之间,增强型子离子全扫描水平限和LOQ在0.2~2 μg/kg之间,方法回收率为64.2%~110.6%, RSD为4.2%~12.5%。阳性样品的定性确证需采用其子离子全扫描质谱图与标准图库中子离子质谱图检索匹配。经测定多种火锅料,表明本方法操作简单、测定结果准确,可用于火锅料中5种生物碱残留的阳性结果确证分析。     

定量蛋白质组学质谱采集技术进展

质谱是定量蛋白组学的主要工具。近年来随着定量蛋白质组学研究的深入,传统质谱定量技术面临着复杂基质干扰、分析通量限制等诸多问题。而最近一系列质谱新技术的发展,包括同步母离子选择( SPS)、质量亏损标记、平行反应监测(PRM)、多重累积(MSX)和多种全新数据非依赖性采集(DIA)等,为解决目前蛋白质组学在相对定量和绝对定量分析方面的局限提供了有效途径。本文对定量蛋白质组学目前遇到的瓶颈问题进行了分析,总结了质谱定量采集技术的最新进展,并评述了这些新技术的特点以及在定量蛋白质组学应用中的优势。     

高效液相色谱-电喷雾串联质谱法测定蜂蜜中的林可胺类抗生素残留

建立了蜂蜜中林可胺类抗生素林可霉素和氯林可霉素的高效液相色谱-电喷雾串联质谱(HPLC/ESI-MS/MS)检测方法。样品经固相萃取提取净化、反相液相色谱分离后进行质谱分析,在选择反应监测模式(SRM) 下进行特征母-子离子对信号采集。根据保留时间、母离子和两个特征子离子信息进行定性分析,以共同的基峰离子m/z 126进行定量。两种抗生素的检测限(S/N=3) 为 0.1 μg/kg,定量限为 0.5 μg/kg,在1.0～200 μg/L时峰强度与质量浓度的线性关系良好(r2>0.996)。在1.0,5.0,20.0 μg/kg 3个添加水平,两种抗生素的平均回收率范围为80%～110%,日内测定结果的相对标准偏差小于8%,日间测定结果的相对标准偏差小于15%。结果表明,该法简单、灵敏,特异性强,适用于蜂蜜中林可胺类抗生素残留的分析确证。     

UPLC-MS/MS法快速筛查尿液中30种滥用药物

基于超高液相色谱-串联四极杆/线性离子阱质谱(QTRAP UPLC-MS/MS),建立了尿液中30种滥用药物的筛查方法。采用蛋白沉淀法处理尿液样品,实现对多类别滥用药物的高效提取。采用分段多反应监测(s MRM)联合信息依赖性采集(IDA)与增强离子扫描(EPI)模式,结合EPI谱库检索匹配确证检出物信息,并引入内标辅助定量。30种滥用药物质量浓度在0.5~50 ng/mL范围内线性关系良好(R²> 0.99);检出限为0.01~0.25 ng/mL,定量限为0.1~0.4 ng/mL;加标回收率为76.2%~112.5%,相对标准偏差为3.1%~12%。该方法适用于实际尿样中痕量滥用药物的定性与定量分析。     

基于特征肽段的液相色谱-质谱技术鉴定胶原蛋白的物种来源

建立了一种基于特征肽段的液相色谱-质谱技术鉴定胶原蛋白物种来源的方法。样品经蛋白提取,还原,烷基化,胰蛋白酶消化后,采用Eksigent C18色谱柱(75μm×150 mm,3μm)分离,用流动相0. 1%甲酸水-乙腈溶液(98∶2)和0. 1%甲酸乙腈-水溶液(98∶2)梯度洗脱,在正离子模式下,通过纳升电喷雾四极杆飞行时间质谱进行检测,数据经Protein PilotTM软件及blast分析,筛选出潜在的特征肽段。消化后的样品再采用Eclipse Plus C18色谱柱(2. 1 mm×100 mm,1. 8μm)分离,用流动相乙腈和1%甲酸水溶液梯度洗脱,在正离子模式下,通过电喷雾四极杆/线性离子阱串联质谱的多反应监测触发增强子离子扫描模式进行检测,进一步确认肽段的特异性。最终筛选并确证了3种猪源性胶原蛋白特征肽段,4种牛源性胶原蛋白特征肽段,1种羊源性胶原蛋白特征肽段。所筛选的特征肽段具有良好的耐热性,可为动物源性胶原蛋白鉴定提供一种特异性强、准确可靠的检测方法。     

离子色谱-质谱联用技术测定污泥样品中的痕量高氯酸盐

建立了离子色谱-质谱联用技术测定活性污泥样品中高氯酸盐的分析方法。以高容量、强亲水性的IonPacAS20(2mm)阴离子交换柱为分析柱,EGC在线产生等浓度KOH为淋洗液,淋洗液经抑制成水后将样品带入质谱检测。ESI-MS-MS以多元反应监测模式监控100.8/84.9、98.8/66.9、100.8/68.9和98.8/82.9离子对,以98.8/82.9离子对的峰面积进行定量。该方法对高氯酸盐的检出限(S/N=3)为0.01μg/L,高氯酸盐在0.05~100μg/L浓度范围内具有良好的线性,线性相关系数r=0.9988。0.2μg/L的标准溶液重复进样9次,高氯酸盐峰面积的相对标准偏差(RSD)为2.3%。运用该方法测定采自不同地区的活性污泥样品中的高氯酸盐,并对样品加标回收,得回收率在88.5%~102.2%之间。     

依赖色谱保留时间的智能化选择反应监测质谱方法的建立及其初步应用

建立了依赖色谱保留时间的智能化选择反应监测质谱方法,并与非依赖色谱保留时间的智能化选择反应监测质谱分析方法对不同体系(牛血清白蛋白酶切物、6种标准蛋白质混合物酶切物、腾冲嗜热菌蛋白提取液酶切物)的分析结果进行了系统比较。结果表明,引入色谱保留时间后的智能化选择反应监测质谱方法能够显著提高肽段及蛋白质的鉴定量,并且在复杂体系（如腾冲嗜热菌蛋白提取液酶切物）中效果尤为明显,鉴定到的肽段及蛋白质的覆盖率可分别达到目标肽段和蛋白质数量的89.62%和92.41%,并且灵敏度高、重复性好,能够实现对质荷比相同但保留时间有差异的肽段的准确鉴定。该方法将在复杂生物样本目标蛋白质组高通量、高灵敏度的鉴定、验证和确认中发挥独特作用。     

Development and validation of a method for the quantification of milk proteins in food products based on liquid chromatography with mass spectrometric detection

The protection of allergic consumers is crucial to the food industry. Therefore, accurate methods for the detection of food allergens are required. Targeted detection of selected molecules by MS combines high selectivity with accurate quantification. A confirmatory method based on LC/selected reaction monitoring (SRM)-MS/MS was established and validated for the quantification of milk traces in food. Tryptic peptides of the major milk proteins beta-lactoglobulin, beta-casein, alphaS2-casein, and K-casein were selected as quantitative markers. Precise quantification was achieved using internal standard peptides containing isotopically labeled amino acids. For each peptide, qualifier and quantifier fragments were selected according to Commission Decision 2002/657/EC. A simple sample preparation method was established without immunoaffinity or SPE enrichment steps for food matrixes containing different amounts of protein, such as baby food, breakfast cereals, infant formula, and cereals. Intermediate reproducibility, repeatability, accuracy, and measurement uncertainty were determined for each matrix. LOD values of 0.2-0.5 mg/kg, e.g., for beta-lactoglobulin, were comparable to those obtained with ELISA kits. An LOQ of approximately 5 mg/kg, expressed as mass fraction skim milk powder, was validated in protein-rich infant cereals. The obtained validation data show that the described LC/SRM-MS/MS approach can serve as a confirmatory method for the determination of milk traces in selected food matrixes.     

A strategy for a post-method-validation use of incurred biological samples for establishing the acceptability of a liquid chromatography/tandem mass-spectrometric method for quantitation of drugs in biological samples

Validated liquid chromatography/tandem mass spectrometric (LC/MS/MS) methods are now widely used for quantitation of drugs in post-dose (incurred) biological samples for the assessment of pharmacokinetic parameters, bioavailability and bioequivalence. In accordance with the practice currently accepted within the pharmaceutical industry and the regulatory bodies, validation of a bioanalytical LC/MS/MS method is performed using standards and quality control (QC) samples prepared by spiking the drug (the analyte) into the appropriate blank biological matrix (e.g. human plasma). The method is then declared to be adequately validated for analyzing incurred biological samples. However, unlike QC samples, incurred samples may contain an epimer or another type of isomer of the drug, such as a Z or E isomer. Such a metabolite will obviously interfere with the selected reaction monitoring (SRM) transition used for the quantitation of the drug. The incurred sample may also contain a non-isomeric metabolite having a molecular mass different from that of the drug (such an acylglucuronide metabolite) that can still contribute to (and hence interfere with) the SRM transition used for the quantitation of the drug. The potential for the SRM interference increases with the use of LC/MS/MS bioanalytical methods with very short run times (e.g. 0.5 min). In addition, a metabolite can potentially undergo degradation or conversion to revert back to the drug during the multiple steps of sample preparation that precede the introduction of the processed sample into the LC/MS/MS system. In this paper, we recommend a set of procedures to undertake with incurred samples, as soon as such samples are available, in order to establish the validity of an LC/MS/MS method for analyzing real-life samples. First, it is recommended that the stability of incurred samples be investigated 'as is' and after sample preparation. Second, it is recommended that potential SRM interference be investigated by analyzing the incurred samples using the same LC/MS/MS method but with the additional incorporation of the SRM transitions attributable to putative metabolites (multi-SRM method). The metabolites monitored will depend on the expected metabolic products of the drug, which are predictable based on the functional groups present in the chemical structure of the drug. Third, it is recommended that potential SRM interference be further investigated by analyzing the incurred samples using the multi-SRM LC/MS/MS method following the modification of chromatographic conditions to enhance chromatographic separation of the drug from any putative metabolites. We will demonstrate the application of the proposed strategy by using a carboxylic acid containing drug candidate and its acylglucuronide as a putative metabolite. Plasma samples from the first-in-man (FIM) study of the drug candidate were used as the incurred samples.     

Application of ion trap technology to liquid chromatography/mass spectrometry quantitation of large peptides

Triple quadrupole mass spectrometers are generally considered the instrument of choice for quantitative analysis. However, for the analysis of large peptides we have encountered some cases where, as the data presented here would indicate, ion trap mass spectrometers may be a good alternative. In general, specificity and sensitivity in bioanalytical liquid chromatography/mass spectrometry (LC/MS) assays are achieved via tandem MS (MS/MS) utilizing collision-induced dissociation (CID) while monitoring unique precursor to product ion transitions (i.e. selected reaction monitoring, SRM). Due to the difference in CID processes, triple quadrupoles and ion traps often generate significantly different fragmentation spectra of product ion species and intensities. The large peptidic analytes investigated here generated fewer fragments with higher relative abundance on the ion trap as compared to those generated on the triple quadrupole, resulting in lower limits of detection on the ion trap.     

Determination of rosamultin in rat plasma by LC–MS/MS and its application to a pharmacokinetic study

A specific and reliable LC–MS/MS method for the determination of rosamultin in rat plasma was validated. Plasma samples were prepared with protein precipitation method, and chromatographic separation was performed on a Thermo C₁₈ analytical column (4.6 mm × 50 mm, 3.0 μm). The mass spectrometry (MS) analysis was conducted in positive SRM mode for the transitions of m/z 673.2 → 511.1 for rosamultin and m/z 601.1 → 330.9 for IS. The method validation was conducted over the calibration range of 1.0–500 ng/mL with the precision ≤11.03% and accuracy within ±14.64%. The assay was applied to the pharmacokinetic study after oral administration of rosamultin at a dose of 20 mg/kg in rats.     

MSQ: a tool for quantification of proteomics data generated by a liquid chromatography/matrix‐assisted laser desorption/ionization time‐of‐flight tandem mass spectrometry based targeted quantitative proteomics platform

Mass spectrometry (MS)‐based quantitative proteomics has become a critical component of biological and clinical research for identification of biomarkers that can be used for early detection of diseases. In particular, MS‐based targeted quantitative proteomics has been recently developed for the detection and validation of biomarker candidates in complex biological samples. In such approaches, synthetic reference peptides that are the stable isotope labeled version of proteotypic peptides of proteins to be quantitated are used as internal standards enabling specific identification and absolute quantification of targeted peptides. The quantification of targeted peptides is achieved using the intensity ratio of a native peptide to the corresponding reference peptide whose spike‐in amount is known. However, a manual calculation of the ratios can be time‐consuming and labor‐intensive, especially when the number of peptides to be tested is large. To establish a liquid chromatography/matrix‐assisted laser desorption/ionization time‐of‐flight tandem mass spectrometry (LC/MALDI TOF/TOF)‐based targeted quantitative proteomics pipeline, we have developed a software named Mass Spectrometry based Quantification (MSQ). This software can be used to automate the quantification and identification of targeted peptides/proteins by the MALDI TOF/TOF platform. MSQ was applied to the detection of a selected group of targeted peptides in pooled human cerebrospinal spinal fluid (CSF) from patients with Alzheimer's disease (AD) in comparison with age‐matched control (OC). The results for the automated quantification and identification of targeted peptides/proteins in CSF were in good agreement with results calculated manually. Copyright © 2010 John Wiley & Sons, Ltd.     

基于共价色谱分离的含半胱氨酸肽段富集策略

多维色谱分离、串联质谱分析技术已在蛋白质组研究中得到广泛应用。然而生物样品的蛋白质以及全酶切肽段具有高度的复杂性,这严重干扰了蛋白质高通量、规模化的分析。通过标签肽段富集进行样品预分离可以降低体系的复杂程度。本文建立了一种基于共价色谱技术选择性分离富集含半胱氨酸肽的方法,从而降低了样品体系的复杂程度。首先以牛血清白蛋白(BSA)的酶切肽段为模型,对富集条件进行了优化和考察,并在此基础上通过5种蛋白质酶切肽段混合物的富集对该方法进行了验证。结果证明此方法的重现性好,富集效率高,富集特异性好,能有效地富集鉴定含半胱氨酸肽段。所建立的方法在复杂体系的蛋白质组研究中具有广泛的应用前景,为复杂样品的蛋白质高通量、自动化、规模化鉴定和定量研究提供了实用技术。     

Bioanalytical strategies for developing highly sensitive liquid chromatography/tandem mass spectrometry based methods for the peptide GLP-1 agonists in support of discovery PK/PD studies

Highly sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS)-based methods have been developed and implemented for the quantitative determination of a number of peptides under evaluation in our Glucagon-Like Peptide-1 (GLP-1) discovery program for the treatment of diabetes. These peptides are GLP-1 receptor agonists. Due to the high potency, low dose, and low exposure of these peptides, LC/MS/MS-based methods with Lower Limits of Quantitation (LLOQs) (low picomolar range) were required to support discovery pharmacokinetic/ pharmacodynamic (PK/PD) studies. Compared with small molecules, many of these peptides posed significant bioanalytical challenges in the development of highly sensitive methods because of their parent signal splitting as a result of the formation of multiply charged states, the unfavorable fragmentation patterns for Selected Reaction Monitoring (SRM) transitions due to the generation of a large number of small mass product ions with relative low intensities, and adsorption issues observed during sample preparation. This paper details the strategies developed to maximize the sensitivity and improve LLOQs from aspects of mass spectrometry, chromatography, and sample preparation. A LLOQ of 10 picomolar was achieved for all of the investigated peptides using 100 μL of mouse plasma. This is a 100-fold improvement on LLOQs over generic LC/MS/MS-based methods when the same sample volume and the same mass spectrometer platform were used. The methods have been implemented in the support of discovery PK/PD studies.     

Selected reaction monitoring (SRM) mass spectrometry without isotope labeling can be used for rapid protein quantification

The validation of putative biomarker candidates has become the major bottle-neck in protein biomarker development. Conventional immunoaffinity methods are limited by the availability of antibodies and kits. Here we demonstrate the feasibility of using selected reaction monitoring (SRM) without isotope labeling to achieve fast and reproducible quantification of serum proteins. The SRM/MRM assays for three standard serum proteins, including ceruloplasmin (CP), serum aymloid A (SAA) and sex hormone binding globulin (SHBG), have good linear ranges, generally 10(3) to 10(4) . There are almost perfect correlations between SRM intensities and the loaded peptide amounts (R(2) is usually ~0.99). Our data suggest that SRM/MRM is able to quantify proteins within the range of 0.2-2 fmol, which is comparable to the commercial ELISA/LUMINEX kits for these proteins. Excellent correlations between SRM/MRM and ELISA/LUMINEX assays were observed for SAA and SHBG (R(2)=0.928 and 0.851, respectively). However, the correlation between SRM/MRM and ELISA for CP is less desirable (R(2)=0.565). The reproducibility for SRM/MRM assays is generally very good but may depend on the proteins/peptides being analyzed (R(2)=0.931 and 0.882 for SAA and SHBG, and 0.723 for CP). The SRM/MRM assay without isotope labeling is a rapid and useful method for protein biomarker validation in a modest number of samples and is especially useful when other assays such as ELISA or LUMINEX are not available.